Defitelio (defibrotide) Disease Interactions
There is 1 disease interaction with Defitelio (defibrotide):
Defibrotide (Includes Defitelio) ↔ Bleeding
Severe Potential Hazard, Moderate plausibility
Applies to: Bleeding
The use of defibrotide may increase the risk of bleeding in patients with hepatic veno-occlusive disease after hematopoietic stem-cell transplantation. Discontinue anticoagulants and fibrinolytic agents prior to defibrotide treatment, and consider delaying the start of defibrotide administration until the effects of the anticoagulant have subsided. It is recommended to withhold therapy with defibrotide in patients with active bleeding and to monitor patients for signs of bleeding. Discontinue treatment with defibrotide in patients that develop bleeding and treat the underlying cause, and provide supportive care until the bleeding has stopped.
Defitelio (defibrotide) drug Interactions
There are 195 drug interactions with Defitelio (defibrotide)
More about Defitelio (defibrotide)
- Defitelio Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: miscellaneous coagulation modifiers
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.